SI0817627T1 - - Google Patents
Info
- Publication number
- SI0817627T1 SI0817627T1 SI9430475T SI9430475T SI0817627T1 SI 0817627 T1 SI0817627 T1 SI 0817627T1 SI 9430475 T SI9430475 T SI 9430475T SI 9430475 T SI9430475 T SI 9430475T SI 0817627 T1 SI0817627 T1 SI 0817627T1
- Authority
- SI
- Slovenia
- Prior art keywords
- beta
- isozyme
- protein kinase
- present
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17374193A | 1993-12-23 | 1993-12-23 | |
US08/324,948 US5545636A (en) | 1993-12-23 | 1994-10-18 | Protein kinase C inhibitors |
PCT/US1994/014313 WO1995017182A1 (en) | 1993-12-23 | 1994-12-14 | Protein kinase c inhibitors |
EP95904892A EP0817627B1 (en) | 1993-12-23 | 1994-12-14 | Protein kinase c inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI0817627T1 true SI0817627T1 (ja) | 2005-08-31 |
Family
ID=26869484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9430475T SI0817627T1 (ja) | 1993-12-23 | 1994-12-14 |
Country Status (13)
Country | Link |
---|---|
US (3) | US5661173A (ja) |
EP (2) | EP1449529B1 (ja) |
JP (4) | JP3998261B2 (ja) |
AT (2) | ATE290378T1 (ja) |
AU (1) | AU1339895A (ja) |
CA (1) | CA2179650C (ja) |
DE (1) | DE69434294T2 (ja) |
DK (1) | DK0817627T3 (ja) |
ES (1) | ES2236702T3 (ja) |
HK (1) | HK1008183A1 (ja) |
PT (1) | PT817627E (ja) |
SI (1) | SI0817627T1 (ja) |
WO (1) | WO1995017182A1 (ja) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2249205A1 (en) * | 1996-03-20 | 1997-09-25 | Eli Lilly And Company | Synthesis of indolylmaleimides |
US6232299B1 (en) * | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
SE9603284D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
SE9603283D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
SE9603285D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
US5859261A (en) * | 1997-03-20 | 1999-01-12 | Eli Lilly And Company | Synthesis of indolylmaleimides |
AR017200A1 (es) | 1997-12-23 | 2001-08-22 | Astrazeneca Ab | Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos |
SE9800835D0 (sv) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
EP1064279B1 (en) * | 1998-03-17 | 2003-06-25 | F.Hoffmann-La Roche Ag | Substituted bisindolylmaleimides for the inhibition of cell proliferation |
WO1999057117A2 (de) | 1998-05-04 | 1999-11-11 | Asta Medica Aktiengesellschaft | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen |
US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
US6284783B1 (en) | 1999-06-09 | 2001-09-04 | The Uab Research Foundation | Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis |
US6346625B1 (en) | 1999-06-23 | 2002-02-12 | Astrazeneca Ab | Protein kinase inhibitors |
CA2341542A1 (en) * | 1999-06-24 | 2000-12-28 | Toray Industries, Inc. | .alpha.1b-adrenergic receptor antagonists |
US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
DE60010934T2 (de) * | 1999-12-16 | 2005-05-19 | Eli Lilly And Co., Indianapolis | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen |
EP1242420A2 (en) | 1999-12-16 | 2002-09-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
US6743785B2 (en) | 1999-12-16 | 2004-06-01 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
HUP0302002A3 (en) * | 2000-05-11 | 2007-02-28 | Consejo Superior Investigacion | Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them |
AU2001271261A1 (en) * | 2000-06-29 | 2002-01-14 | Eli Lilly And Company | Therapeutic treatment of cancer with a protein kinase c inhibitor |
AU2001271257A1 (en) * | 2000-06-29 | 2002-01-14 | Eli Lilly And Company | Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy |
MXPA03005140A (es) | 2000-12-08 | 2004-10-15 | Johnson & Johnson | Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa. |
AU2003238874A1 (en) | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Bisindolyl-maleimid derivatives as kinase inhibitors |
DE60323749D1 (de) | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
ES2307059T3 (es) * | 2003-10-24 | 2008-11-16 | Eli Lilly And Company | Bisindolilmaleimidas utiles para tratar el cancer de prostata y enfermedades mediadas por akt. |
GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
CA2599611C (en) | 2005-02-09 | 2013-07-30 | Chiang J. Li | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
WO2006108270A1 (en) * | 2005-04-11 | 2006-10-19 | Pharmagap Inc. | Inhibitors of protein kinases and uses thereof |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
KR20080023732A (ko) * | 2005-07-11 | 2008-03-14 | 노파르티스 아게 | 인돌릴말레이미드 유도체 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
WO2009002806A1 (en) | 2007-06-22 | 2008-12-31 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
BRPI0813355A2 (pt) | 2007-06-22 | 2014-12-30 | Arqule Inc | Compostos de quinazolinona e métodos de uso dos mesmos |
CA2912546A1 (en) | 2007-06-22 | 2008-12-31 | Arqule, Inc. | Compositions and methods for treatment of cancer |
KR20100093129A (ko) | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
WO2010019225A1 (en) * | 2008-08-15 | 2010-02-18 | Robert Shorr | Pharmaceutical composition |
AU2009330492A1 (en) | 2008-12-15 | 2010-07-01 | Eli Lilly And Company | Enzastaurin for the treatment of cancer |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
RU2012146083A (ru) | 2010-03-30 | 2014-05-10 | Новартис Аг | Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
CN103476777B (zh) | 2011-01-31 | 2015-05-27 | 诺瓦提斯公司 | 新杂环衍生物 |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
PT2825542T (pt) | 2012-03-16 | 2016-12-20 | Vitae Pharmaceuticals Inc | Modeladores do recetor x do fígado |
US9006244B2 (en) | 2012-03-16 | 2015-04-14 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
RU2630975C2 (ru) | 2012-05-16 | 2017-09-15 | Новартис Аг | Режим дозирования pi-3 киназы |
HUE037618T2 (hu) | 2012-11-29 | 2018-09-28 | Novartis Ag | Gyógyszerészeti kombinációk |
WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
KR20160095035A (ko) | 2013-12-06 | 2016-08-10 | 노파르티스 아게 | 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법 |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
CN104398508B (zh) * | 2014-11-28 | 2017-06-13 | 上海交通大学 | 双吲哚马来酰亚胺衍生物在制备治疗慢性粒细胞白血病药物中的应用 |
MX2018005298A (es) | 2015-11-02 | 2018-06-22 | Novartis Ag | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |
JP7011596B2 (ja) * | 2015-12-02 | 2022-02-10 | アストライア セラピューティクス, エルエルシー | ピペリジニルノシセプチン受容体化合物 |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
CN110218206B (zh) * | 2016-06-01 | 2022-03-04 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
CN110526903B (zh) * | 2016-06-01 | 2021-12-10 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
WO2019000224A1 (zh) * | 2017-06-27 | 2019-01-03 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4785085A (en) * | 1986-11-21 | 1988-11-15 | Bristol-Myers Company | Rebeccamycin analogs |
US4808613A (en) * | 1986-11-21 | 1989-02-28 | Bristol-Myers Company | Rebeccamycin derivative containing pharmaceutical composition |
EP0303697B1 (en) * | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
DE3803620A1 (de) * | 1988-02-06 | 1989-08-17 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
SK278989B6 (sk) * | 1988-02-10 | 1998-05-06 | F. Hoffmann-La Roche Ag | Substituované pyroly, ich použitie na výrobu lieči |
MC2096A1 (fr) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
DE3942991A1 (de) * | 1989-12-27 | 1991-07-04 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
IL94274A0 (en) | 1989-05-05 | 1991-03-10 | Goedecke Ag | Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same |
DE3914764A1 (de) * | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
DE3942296A1 (de) * | 1989-12-21 | 1991-06-27 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung |
DE4005969A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
DE4005970A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
CA2046801C (en) * | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
WO1992016517A1 (en) * | 1991-03-22 | 1992-10-01 | Xenova Limited | Pharmaceutical xanthone derivatives |
GB9123396D0 (en) * | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
AU3761393A (en) * | 1992-03-20 | 1993-10-21 | Wellcome Foundation Limited, The | Indole derivatives with antiviral activity |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
DE4243321A1 (de) * | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
AU678435B2 (en) * | 1993-05-10 | 1997-05-29 | F. Hoffmann-La Roche Ag | Substituted pyrroles |
US5481003A (en) * | 1994-06-22 | 1996-01-02 | Eli Lilly And Company | Protein kinase C inhibitors |
-
1994
- 1994-12-14 DK DK95904892T patent/DK0817627T3/da active
- 1994-12-14 DE DE69434294T patent/DE69434294T2/de not_active Expired - Lifetime
- 1994-12-14 AT AT95904892T patent/ATE290378T1/de active
- 1994-12-14 EP EP04102054A patent/EP1449529B1/en not_active Expired - Lifetime
- 1994-12-14 WO PCT/US1994/014313 patent/WO1995017182A1/en active IP Right Grant
- 1994-12-14 AU AU13398/95A patent/AU1339895A/en not_active Abandoned
- 1994-12-14 AT AT04102054T patent/ATE456367T1/de not_active IP Right Cessation
- 1994-12-14 ES ES95904892T patent/ES2236702T3/es not_active Expired - Lifetime
- 1994-12-14 JP JP51747995A patent/JP3998261B2/ja not_active Expired - Lifetime
- 1994-12-14 PT PT95904892T patent/PT817627E/pt unknown
- 1994-12-14 SI SI9430475T patent/SI0817627T1/xx unknown
- 1994-12-14 EP EP95904892A patent/EP0817627B1/en not_active Expired - Lifetime
- 1994-12-14 CA CA002179650A patent/CA2179650C/en not_active Expired - Lifetime
-
1995
- 1995-05-25 US US08/450,320 patent/US5661173A/en not_active Expired - Lifetime
- 1995-05-25 US US08/452,606 patent/US5672618A/en not_active Expired - Lifetime
- 1995-05-25 US US08/452,617 patent/US5668152A/en not_active Expired - Lifetime
-
1998
- 1998-07-14 HK HK98109161A patent/HK1008183A1/xx not_active IP Right Cessation
-
2005
- 2005-05-09 JP JP2005135900A patent/JP4369397B2/ja not_active Expired - Lifetime
- 2005-05-09 JP JP2005135896A patent/JP4365803B2/ja not_active Expired - Lifetime
-
2006
- 2006-07-20 JP JP2006198260A patent/JP4490400B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2006316068A (ja) | 2006-11-24 |
PT817627E (pt) | 2005-07-29 |
JP4369397B2 (ja) | 2009-11-18 |
US5661173A (en) | 1997-08-26 |
ATE456367T1 (de) | 2010-02-15 |
EP0817627A1 (en) | 1998-01-14 |
CA2179650A1 (en) | 1995-06-29 |
JP4365803B2 (ja) | 2009-11-18 |
CA2179650C (en) | 2007-10-30 |
JP2005225896A (ja) | 2005-08-25 |
JP2005225895A (ja) | 2005-08-25 |
US5668152A (en) | 1997-09-16 |
HK1008183A1 (en) | 1999-05-07 |
JPH09507066A (ja) | 1997-07-15 |
ATE290378T1 (de) | 2005-03-15 |
ES2236702T3 (es) | 2005-07-16 |
AU1339895A (en) | 1995-07-10 |
DE69434294D1 (de) | 2005-04-14 |
EP0817627B1 (en) | 2005-03-09 |
US5672618A (en) | 1997-09-30 |
EP1449529B1 (en) | 2010-01-27 |
EP0817627A4 (en) | 2002-07-17 |
DK0817627T3 (da) | 2005-06-06 |
DE69434294T2 (de) | 2005-12-29 |
JP4490400B2 (ja) | 2010-06-23 |
WO1995017182A1 (en) | 1995-06-29 |
JP3998261B2 (ja) | 2007-10-24 |
EP1449529A1 (en) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI0817627T1 (ja) | ||
GR3037074T3 (en) | Protein kinase c inhibitors | |
BG103671A (en) | Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes | |
CA2376596A1 (en) | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies | |
EP1040827A3 (en) | Use of 2-alkylpyrrolidines for the treatment of diabetes | |
AU6875694A (en) | A wood preservative composition, process for treating wood with the same, and wood treated with the same | |
NZ324921A (en) | Cathepsin K crystal structure and methods of identifying inhibitors of this protease | |
AU1645995A (en) | Leather treatment process for leather coloring, leather coloring process performed on leather thereby treated, and leather article produced by the leather coloring process | |
GB2297691B (en) | Method for improving breeding activity of boars by using feed for the breeding boars | |
WO1995006764A3 (en) | Oligonucleotides with rna cleavage activity | |
WO2000021513A3 (en) | Methods for treating multiple sclerosis | |
ZA971772B (en) | Process for treating wood. | |
WO1993015112A3 (en) | COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION | |
IT1240486B (it) | Procedimento di ammollo enzimatico per pelli e pellami. | |
WO1999033494A3 (en) | Method and apparatus for aerating chemically-sterilized articles | |
IL142220A0 (en) | Method of treating viral hemorrhagic fever | |
WO2000000634A3 (en) | METHODS OF INHIBITING $i(HELICOBACTER PYLORI) | |
WO1997035967A3 (en) | Transgenic organisms with altered telomerase activity | |
IL142255A0 (en) | Method of treating heparin-induced thrombocytopenia | |
EP0398416A3 (en) | Process for isomerising hydrocarbons | |
EP0624746A3 (de) | Sperrventil. | |
EP0646651A3 (en) | Method for improving the treatment of leather. | |
CA2193703A1 (en) | Protein kinase c inhibitors | |
CA2353982A1 (en) | Recovery of hydrocarbons in oil wells by injection of treated inert gases obtained from the industrial effluence | |
EP0950411B8 (de) | Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes |